SEC Company Response from Nomadar (NOMA) — Aug 25, 2025
Nomadar Corp.
Date: Aug. 25, 2025 · CIK: 0001994214 · Accession: 0001641172-25-025426
AI Filing Summary & Sentiment
File numbers found in text: 333-284716
Referenced dates: August 13, 2025
Show Raw Text
CORRESP
1
filename1.htm
Jeffrey
Baumel
Jeffrey.baumel@dentons.com
D
+1 973 912 7189
Dentons
US LLP
1221
Avenue of the Americas
New
York, NY 10020-1089
United
States
dentons.com
August
25, 2025
Privileged
and Confidential
VIA
EDGAR
Kate
Beukenkamp
Donald
Field
Ta
Tanisha Meadows
Adam
Phippen
Securities
and Exchange Commission
Division
of Corporation Finance
Office
of Trade & Services
100
F Street, N.E.
Washington,
DC 20549
Re:
Nomadar
Corp.
Amendment
No. 3 to Registration Statement on Form S-1
Filed
August 7, 2025
File
No. 333-284716
Dear
Ms. Beukenkamp and Mr. Field:
By
your letter dated August 13, 2025 (the “SEC Letter”), the staff of the Division of Corporation Finance of the Securities
and Exchange Commission (the “Staff”) provided comments to Amendment No. 3 (the “Amendment No. 3”) to
the Registration Statement on Form S-1 (the “Registration Statement”), filed with the Staff on August 7, 2025, by
our client, Nomadar Corp. (the “Company”). This letter sets forth the Company’s response with respect to the
comments contained in the SEC Letter.
Concurrently
herewith, we are filing Amendment No. 4 to the Registration Statement (“Amendment No. 4”) via the EDGAR system. The
changes made to the Registration Statement reflect the responses of the Company to the Staff’s comments as set forth in the SEC
Letter regarding Amendment No. 3.
The
Company has asked us to convey the following as its responses to the Staff.
Amendment
No. 3 to the Registration Statement on Form S-1
Capitalization,
page 38
1.
We
reviewed your revisions in response to prior comment 1. We note that you include “Total Liabilities.” Please tell us
your consideration of including only debt. In other words, please tell us your consideration of not including accounts payable, accrued
expenses and deferred revenue. In addition, please tell why pro forma accumulated deficit is different than actual. Finally, please
explain why pro forma additional paid-in capital increased by $8,500,000 rather than $7,500,000 related to the 750,000 shares issued.
Response:
The Company respectfully advises the Staff that the Company’s unaudited financial information as of, and for the period ended, June 30, 2025, is included in Amendment No. 4. As
a result, the pro forma information and the table set forth on page 38, have been removed from the Registration Statement.
August
25, 2025
Page
2
dentons.com
Certain
Relationships and Related Party Transactions, page 69
2.
We
note your response to prior comment 3, including filing the agreement as Ex. 10.14, and reissue in part. Specifically, please disclose
the material terms of the agreement, including but not limited to, the duration of the agreement, termination, and payment structure.
We note your statement that “All specific services to be provided by Cádiz CF to Nomadar or by Nomadar to Cádiz
CF, and related payments to be made from Cádiz CF to Nomadar or by Nomadar to Cádiz CF, will be set forth in subsequent
annexes.” Therefore, if these terms are not currently known or are being negotiated, please expand your discussion to state
plainly that is the case. Additionally, please revise your risk factors section as applicable to account for the risk that these
terms have not yet been determined, including the risks associated with the uncertainty of receiving revenue associated with the
Framework Agreement.
Response:
The Company respectfully advises the Staff that it has revised Amendment No. 4 to disclose the material terms of the Framework
Agreement. Additionally, the Company has revised the risk factors section to account for the risks associated with the uncertainty
of receiving revenue associated with the Framework Agreement. Please see pages 1, 27, 39, and 69, of Amendment No. 4.
If
you have any questions, or if we may be of any assistance, please do not hesitate to contact the undersigned at 973-912-7189 or Jeffrey.baumel@dentons.com
or Grant Levine at 212-768-5384 or grant.levine@dentons.com, respectively.
Very
truly yours,
/s/
Jeffrey Baumel
Jeffrey
Baumel
JB